Skip to main content
COVID-19 Update: Many people are being asked to stay home to slow the spread of COVID-19... Many people are being asked to stay home to slow the spread of COVID-19. INBRIJA® (levodopa inhalation powder) continues to be delivered directly to patients' residences, so you can still receive your medication even if you are homebound for a prolonged period of time...
Patient Information For US Residents Only

Savings Programs

Paying for INBRIJA®

If you or someone you care for wants to know how they can save when starting INBRIJA, there are options. See below for the different savings programs that are offered to help you when starting INBRIJA.

Free Trial Program

If your doctor thinks INBRIJA is right for you, you may qualify for the INBRIJA FREE trial program. Eligible commercially-insured or cash-pay patients can get access to 1 carton (30 doses) of INBRIJA at no cost.

Co-Pay Program

Prescription Support Services can confirm whether your insurance will cover your prescription and whether you are eligible for our co‑pay assistance program. If you have commercial insurance (employer‑sponsored or individual) and INBRIJA is covered, you may be eligible for co‑pay assistance for INBRIJA where allowed by law. Patients who participate in Medicaid, Medicare, or any other federal healthcare program are not eligible to receive co‑pay assistance.

Patient Assistance Program

If you cannot afford INBRIJA, Prescription Support Services may be able to help. You may be eligible for the Patient Assistance Program which is designed to help you get INBRIJA at no cost. Ask us for more information about the program and how to apply.

Medicare Extra Help Program

If you are enrolled in Medicare and have limited financial resources, you may qualify for the Medicare Extra Help program to help pay for some healthcare and prescription drug costs. Ask us for details about how to apply for the program. The Medicare Extra Help program is a federal program, and is not managed by Acorda.

Get the support you need

If you have questions about INBRIJA or would like to speak with a Nurse Educator for additional training tips, please contact Prescription Support Services directly.

Call toll-free 1‑888‑887‑3447

8 AM to 8 PM Eastern Time, Monday through Friday

Common Questions

Show Answers

What if I can’t afford INBRIJA?

If you have commercial insurance (employer sponsored or individual) and INBRIJA is covered, you may be eligible for co-pay assistance for INBRIJA where allowed by law. Patients who participate in Medicaid, Medicare, or any other federal healthcare program are not eligible to receive co‑pay assistance.

If you cannot afford INBRIJA, Prescription Support Services may be able to help. You may be eligible for the Patient Assistance Program which is designed to help you get INBRIJA at no cost. Ask us for more information about the program and how to apply.

If you are enrolled in Medicare and have limited financial resources, you may qualify for the Medicare Extra Help program to help pay for some healthcare and prescription drug costs. Ask us for details about how to apply for the program. The Medicare Extra Help program is a federal program, and is not managed by Acorda.

What support does Prescription Support Services provide?

Prescription Support Services specialists work with your doctor and specialty pharmacy to get you started on INBRIJA. They confirm your coverage and out‑of‑pocket expenses, and help to answer questions you may have about your coverage. In addition, Nurse Educators are available to provide further training tips and answer any questions you may have on how to use INBRIJA. Our Nurse Educators are available to help Monday through Friday, 8 AM to 8 PM Eastern Time. To reach Nurse Educators, call toll‑free at 1‑888‑887‑3447.

Whom can I contact if I have additional questions?

If you have additional questions about INBRIJA, feel free to call Prescription Support Services (1‑888‑887‑3447). Contact your doctor if you have questions about your medical care.

See full list of
common questions

INBRIJA® Indication

Treats OFF periods in adults taking carbidopa/levodopa (CD/LD). INBRIJA doesn’t replace CD/LD.

Important Safety Information

Don’t use if you have taken a nonselective monoamine oxidase inhibitor (eg, phenelzine, tranylcypromine) within the last 2 weeks.

Indication

INBRIJA is a prescription medicine used when needed for OFF episodes in adults with Parkinson’s treated with regular carbidopa/levodopa medicine. INBRIJA does not replace regular carbidopa/levodopa medicine.

Important Safety Information

Do not use INBRIJA if you take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last 2 weeks.

Before using INBRIJA, tell your healthcare provider about your medical conditions, including:

  • asthma, chronic obstructive pulmonary disease (COPD), or any chronic lung disease
  • daytime sleepiness, sleep disorders, sleepiness/drowsiness without warning, or use of medicine that increases sleepiness, including antidepressants or antipsychotics
  • dizziness, nausea, sweating, or fainting when standing up
  • abnormal movement (dyskinesia)
  • mental health problems such as hallucinations or psychosis
  • uncontrollable urges like gambling, sexual urges, spending money, or binge eating
  • glaucoma
  • pregnancy or plans to become pregnant. It is unknown if INBRIJA will harm an unborn baby.
  • breastfeeding or plans to breastfeed. Levodopa can pass into breastmilk and it is unknown if it can harm the baby.

Tell your healthcare provider if you take:

  • MAO-B inhibitors
  • dopamine (D2) antagonists (including phenothiazines, butyrophenones, risperidone, metoclopramide)
  • isoniazid
  • iron salts or multivitamins that contain iron salts

Do not drive, operate machinery, or do other activities until you know how INBRIJA affects you. Sleepiness and falling asleep suddenly can happen as late as a year after treatment is started.

Tell your healthcare provider if you experience the following side effects:

  • falling asleep during normal daily activities with or without warning. If you become drowsy, do not drive or do activities where you need to be alert. Chances of falling asleep during normal activities increases if you take medicine that cause sleepiness.
  • withdrawal-emergent hyperpyrexia and confusion (fever, stiff muscles, or changes in breathing and heartbeat) if you suddenly stop using INBRIJA or carbidopa/levodopa, or suddenly lower your dose of carbidopa/levodopa.
  • low blood pressure when standing up (that may be with dizziness, fainting, nausea, and sweating). Get up slowly after sitting/lying down.
  • hallucinations and other psychosis – INBRIJA may cause or worsen seeing/hearing/believing things that are not real; confusion, disorientation, or disorganized thinking; trouble sleeping; dreaming a lot; being overly suspicious or feeling people want to harm you; acting aggressive; and feeling agitated/restless.
  • unusual uncontrollable urges such as gambling, binge eating, shopping, and sexual urges has occurred in some people using medicine like INBRIJA.
  • uncontrolled, sudden body movements (dyskinesia) may be caused or worsened by INBRIJA. INBRIJA may need to be stopped or other Parkinson’s medicines may need to be changed.
  • bronchospasm – people with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.
  • increased eye pressure in patients with glaucoma. Your healthcare provider should monitor this.
  • changes in certain lab values including liver tests

The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Do not orally inhale more than 1 dose (2 capsules) for any OFF period. Do not take more than 5 doses (10 capsules) in a day.

Please see the Patient Information Leaflet.